CSL wipes $10 billion in value on a Vifor writedown and guidance cut

One of the largest single-day writedowns in Australian corporate history has forced fund managers to confront whether CSL's plasma and immunoglobulin business is facing a temporary reset or a more structural challenge, just as the company searches for a new chief executive.

24 Jul 2026 · 6 min read

CSL Ltd (ASX: CSL) delivered one of the largest single-day value destructions in Australian corporate history in May 2026, forcing fund managers into a genuine reassessment of whether its long-standing quality premium still holds. Pendal Group detailed the scale of the reset: CSL downgraded FY26 earnings guidance from expected NPATA growth of 4-7% to an expected decline of around 4%, driven partly by the company taking inventory out of a lower-priced US immunoglobulins channel, a roughly $300 million revenue hit, alongside continued regulatory-driven weakness in Chinese demand for albumin.

While a disappointing outcome, this should set up for a tighter market and a better result in FY27... Despite some signs that the business should perform better in FY27 the market still reduced earnings by 13% in forward years with only minor growth forecast in FY27.

Pendal Group, Newsletter, May 2026

A $5 billion writedown centred on Vifor

The earnings downgrade was compounded by an accounting reckoning. Pendal Group reported CSL took an additional $5 billion writedown centred on its disappointing Vifor acquisition from 2022, alongside confirmation the company was in the process of finding a new CEO. Ten Cap's Jun Bei Liu, whose fund has profited from a short position in CSL, described the writedown as one of the biggest in Australian corporate history, prompting investors to wipe almost $10 billion off the stock's value, and argued that blue-chip downgrades of this size are rarely fully priced in ahead of time despite market assumptions to the contrary.

Most people thought CSL was cheap trading at 18 times earnings, and then it went to 15 times, and then it keeps going lower... it is now blue chips where most people think these downgrades are priced in, but they never are, so share prices are very volatile when the downgrade does come through.

Ten Cap, Article, May 2026

Contagion into Cochlear-linked healthcare names

The damage extended beyond CSL's own fundamentals. Investors Mutual Limited reported CSL fell 11.7% in sympathy with an unrelated downgrade from Cochlear, even though the fund viewed the stock as trading at an extremely low valuation given the recurring, defensive nature of its plasma-derived earnings, retaining it as a top-10 holding at a 3.6% portfolio weight. Antares Capital, which does not own CSL, noted the stock also reacted negatively when the US Department of War removed its mandatory flu vaccine requirement for Joint Force members, adding a policy-driven headwind on top of the earnings reset and a wave of price target cuts from sell-side analysts.

A new CEO with deep company history takes the helm

The leadership transition has become a focal point for several holders trying to gauge whether the reset marks a bottom. Ausbil Investment Management struck a constructive tone on new chief executive Gordon Naylor, a 30-year company veteran and former CFO tasked with accelerating CSL's strategic transformation, arguing the current valuation looks more moderate relative to its own history and peers, and that it would not take much of a positive surprise for the stock to re-rate back to a higher multiple. Katana Asset Management took a more cautious wait-and-see stance, describing CSL as a high-quality core business trading at an all-time low valuation, but saying it was awaiting the new CEO appointment before further developing its view.

Long-term holders see the reset as an opportunity, some pull back regardless

Perennial Partners framed the broader healthcare sector sell-off as overdone even while acknowledging real near-term headwinds, arguing very good long-term valuation opportunities are now presenting themselves in a sector where sentiment remains deeply negative. Pendal Group's own view was that fears over structural issues in the key plasma market were overdone, with the stock now trading at a material valuation discount to the market that reflects the market's desire to see proof of better performance rather than a genuine deterioration in the underlying business. Not every holder shares that conviction: Hyperion Asset Management noted it had significantly reduced its weight in CSL the prior year, arguing that even for a high-quality business, it is prudent to hold a lower weight until there is greater clarity on where future growth will come from.

What managers are watching next

With Alliance Bernstein describing itself as a nuanced hold, acknowledging CSL is an interesting company with a lot built into the price but one that has done real damage to shareholder confidence, the catalysts fund managers are tracking are the appointment of a permanent CEO to replace the outgoing leadership, whether the US immunoglobulin channel inventory reduction produces the tighter, better FY27 market Pendal Group expects, and whether Chinese albumin demand stabilises as CSL seeks new channels to market.